An improvement in segregation of human butyrylcholinesterase phenotypes having the fluoride-resistant variants

Arhiv za Higijenu Rada i Toksikologiju

Volumn 54, Issue 4, 2003, Pages 239-244

  Kovarik, Zrinka ^a   Simeon Rudolf, Vera ^a  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

Fluoride resistant variants; Human butyrylcholinesterase; Inhibition; Ro 02 0683; Succinyldicholine

Indexed keywords

(2 HYDROXY 5 PHENYLBENZYL)TRIMETHYLAMMONIUM BROMIDE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; FLUORIDE; MUSCLE RELAXANT AGENT; RO 020683; SUXAMETHONIUM; TRIMETHYLAMMONIUM SALT DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; PHARMACOGENETICS; PHENOTYPE;

BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DIBUCAINE; HUMANS; PHENOTYPE; QUATERNARY AMMONIUM COMPOUNDS; SODIUM FLUORIDE;

EID: 1042302906     PISSN: 00041254     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ashani Y. Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled/release drugs. Drug Dev Res 2000;50:298-308.
2. Lockridge O, Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology 2000;21(1-2):113-26.
3. Evans RT. Cholinesterase phenotyping: clinical aspects and laboratory applications. CRC Crit Rev Clin Lab Sci 1986;23:35-64.
4. Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther 1990;47:35-60.
5. Whittaker M. Cholinesterase. In: Beckman L, editor. Monographs in human genetics. Basel: Karger; 1986. p. 1-32.
6. Primo-Parmo SL, Bartels CF, Wiersema B, Van Der Spek AFL, Innis JW, La Du BN. Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Am J Hum Genet 1996;58:52-64.
7. Nogueira CP, Bartels CF, McGuire MC, Adkins S, Lubrano T, Rubinstein HM, et al. Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase. Am J Hum Genet 1992;51:821-28.
8. Harris H, Whittaker M, Differential inhibition of human serum cholinesterase with fluoride: recognition of new phenotypes. Nature 1961;191:3898-904.
9. Prester Lj, Simeon V. Kinetics of the inhibition of human serum cholinesterase phenotypes with the dimethylcarbamate of (2-hydroxy-5-phenylbenzyl)-trimethylammonium bromide (Ro 02-0683). Biochem Pharmacol 1991;42:2313-6.
10. Simeon-Rudolf V, Kovarik Z, Škrinjarić-Špoljar M, Evans RT. An explanation of different inhibitory characteristics of human serum butyrylcholinesterase phenotypes deriving from inhibition of atypical heterozygotes. Chem Biol Interact 1999;199-120:159-64.
11. Kovarik Z, Radić Z, Grgas B, Škrinjarić-Š poljar M, Reiner E, Simeon-Rudolf V. Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline. Biochim Biophys Acta 1999;1433:261-71.
12. Simeon-Rudolf V, Evans RT. Interlaboratory study into the proficiency of attribution of human serum butyrylcholinesterase phenotypes: Reference values of activities and inhibitor numbers. Acta Pharm 2001;51:289-96.
13. Ellman GL, Courtney KD, Andres Jr V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
14. Eyer P, Worek F, Kiderlen D, Sinko G, Stuglin A, Simeon-Rudolf V, et al. Molar absorption coefficients for the reduced Ellman reagent: reassessment. Anal Biochem 2003;312:224-7.
15. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van Der Spek AF, et al. Identification of the structural mutation responsible for the dibucain-resistant (atypical) variant form of human serum butyrylcholinesterase. Proc Natl Acad Sci USA1989;86:953-7.
16. Kovarik Z. Amino acid residues conferring specificity of cholinesterases. Period biol 1999;101:7-15.
17. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003;278:41141-7.
18. Masson P, Adkins S, Gouet P, Lockridge O. Recombinant human butyrylcholinesterase G390V, the fluoride-2 variant, expressed in Chinese hamster ovary cells, is a low affinity variant. J Biol Chem 1993;268:14329-41.